경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.
로그인 후 질문을 입력해주세요
소개영상보기
Public Health
Hair Loss Recognized as Disease from Follicle Damage
In recent academic discourse, there is growing recognition of hair loss as a disease of modern people. Getty Images Bank After President Lee Jae-myung stated during the Ministry of Health and Welfare’s year-end 2025 policy briefing that “hair loss is a matter of survival,” controversy has reignited in political circles over whether hair loss treatment should be covered by the National Health Insur
2026.02.02
MedTech
Celltrion Internalizes Hyaluronidase SC Formulation Technology
2026.02.02
MedTech
OLED “Hair-Loss Cap” Claims 92% Cell Aging Cut
2026.02.01
MedTech
Korean Team Develops Light-Based Cancer Cell Therapy
2026.02.06
Global Business
Korea United Pharm speeds Vietnam push, targets double cancer drug sales
2026.02.05
Recent Articles
-
AI HealthcareAI Coronary Flow Analysis Boosts Gangnam Hospital PrecisionCoronary intervention being performed. Hallym University Kangnam Sacred Heart Hospital announced that it has become the first among hospitals under Hallym University Medical Center to introduce the latest artificial intelligence (AI)-based coronary blood flow analysis system, “μFR AngioPlus Core” (μ2026.02.11 -
Public HealthKorea’s Pneumonia NIP Should Shift to Conjugate VaccinePneumonia has early symptoms such as cough and fever that are similar to those of a common cold, making early recognition and response difficult and making it hard for patients to perceive warning signs. In particular, among older adults, pneumonia can rapidly progress to a severe stage in a short p2026.02.11 -
Global ExpansionK-Medicine Transforms Arthritis Care With Cartilage RegenerationAnselm Muegele (54, left), who came from Germany to Gangnam JS Hospital for articular cartilage restoration surgery and bowleg correction surgery, and Hospital Director Kim Na-min. Provided by Gangnam JS Hospital “As my knees improved, my life improved as well.”This is what patients who have undergo2026.02.11 -
Global ExpansionCelltrion’s Remsima Tops KRW 1 Trillion Sales AgainCelltrion’s autoimmune disease treatment “Remsima (ingredient name: infliximab)” has surpassed annual sales of KRW 1 trillion for the second consecutive year, firmly maintaining its position as Korea’s first global blockbuster pharmaceutical product. Industry assessments attribute this performance t2026.02.10 -
MedTech‘Immune Shield’ Developed to Halt Organ RejectionⓒNewsis The biggest challenge in organ transplantation, immune rejection, can now be suppressed without side effects thanks to a newly developed technology. Pohang University of Science and Technology (POSTECH) announced on the 9th that, together with a research team from Ewha Womans University, it2026.02.10 -
BiopharmaTargeted Cancer Radiopharmaceuticals Intensify Global Crown RaceThe market for radiopharmaceuticals (RPT), which selectively eliminate only cancer cells, has been expanding rapidly in recent years. Because radioactive substances that are highly effective at destroying cancer cells can be targeted exclusively at those cells, these drugs have the advantage of fewe2026.02.10 -
MedTechPOSTECH Develops Sprayable Immunosuppressant for TransplantsAI-generated image The most significant challenge in organ transplantation, immune rejection, may be suppressed without side effects thanks to a newly developed technology. Pohang University of Science and Technology (POSTECH) announced on the 9th that, together with a research team from Ewha Womans2026.02.09 -
Bio & Pharma / Global HealthKorea United Pharm Speeds UN Cancer Drug SupplyKorea United Pharm Inc. announced on the 9th that it is substantially increasing its supply of anticancer drugs in the public procurement market targeting the UN and international organizations. This initiative is being pursued through cooperation with Denmark-based Missionpharma.Korea United Pharm2026.02.09 -
AI BiotechExclusive: “Another Pandemic Looms—We Must Use AI”Richard Hatchett, Chair of the Coalition for Epidemic Preparedness Innovations (CEPI), explains the importance of using artificial intelligence (AI) in vaccine development during an interview with the Dong-A Ilbo at an event venue in Yongsan-gu, Seoul, on the 6th. Shin Won-geon, Reporter, laputa@don2026.02.09 -
Pharmaceutical R&DPharmaResearch Wins FDA Nod for Phase 1 Nanocancer DrugPharmaResearch announced on the 6th that its next-generation nano anticancer agent under development, “PRD-101,” has received clearance for a Phase 1 clinical trial (IND) from the U.S. Food and Drug Administration (FDA).PRD-101 is a nano anticancer agent that applies nucleotides manufactured using P2026.02.06
